TransMedics Group (NASDAQ:TMDX) Given New $88.00 Price Target at UBS Group

TransMedics Group (NASDAQ:TMDX) had its price objective increased by equities researchers at UBS Group from $77.00 to $88.00 in a research report issued on Monday, Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group‘s price target suggests a potential downside of 6.19% from the stock’s current price.

Several other research firms have also recently weighed in on TMDX. Needham & Company LLC increased their price target on shares of TransMedics Group from $106.00 to $110.00 and gave the company a “buy” rating in a report on Friday. Barclays initiated coverage on TransMedics Group in a report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price objective for the company. TD Cowen restated a “buy” rating and set a $120.00 price objective on shares of TransMedics Group in a report on Tuesday, September 8th. Wall Street Zen raised TransMedics Group from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings upgraded TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Five equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $113.30.

TransMedics Group Stock Performance

TransMedics Group stock traded up $5.56 during mid-day trading on Monday, hitting $93.80. 1,364,041 shares of the company’s stock traded hands, compared to its average volume of 1,020,811. The firm has a 50 day simple moving average of $79.61 and a two-hundred day simple moving average of $93.17. TransMedics Group has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of 25.42, a P/E/G ratio of 1.18 and a beta of 2.14. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.53 and a quick ratio of 4.15.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.30 by $0.21. The company had revenue of $203.01 million during the quarter, compared to analysts’ expectations of $178.06 million. TransMedics Group had a net margin of 19.85% and a return on equity of 13.30%. TransMedics Group’s quarterly revenue was up 41.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.66 EPS. On average, research analysts expect that TransMedics Group will post 1.50 EPS for the current fiscal year.

Insider Activity

In other TransMedics Group news, Director David Weill bought 1,336 shares of TransMedics Group stock in a transaction dated Friday, September 11th. The stock was bought at an average price of $81.63 per share, with a total value of $109,057.68. Following the completion of the transaction, the director owned 16,392 shares in the company, valued at $1,338,078.96. The trade was a 8.87% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently bought and sold shares of the business. Braidwell LP raised its position in TransMedics Group by 85.1% during the second quarter. Braidwell LP now owns 609,715 shares of the company’s stock valued at $40,497,000 after purchasing an additional 280,324 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in TransMedics Group by 5.5% in the first quarter. Dimensional Fund Advisors LP now owns 516,679 shares of the company’s stock valued at $51,355,000 after buying an additional 26,969 shares in the last quarter. Wellington Management Group LLP grew its position in TransMedics Group by 6.1% during the 2nd quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock worth $34,271,000 after acquiring an additional 29,500 shares during the last quarter. Congress Asset Management Co. grew its holdings in TransMedics Group by 11.0% during the 3rd quarter. Congress Asset Management Co. now owns 252,952 shares of the company’s stock worth $21,109,000 after acquiring an additional 25,118 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of TransMedics Group by 19.4% in the 1st quarter. Principal Financial Group Inc. now owns 231,433 shares of the company’s stock valued at $23,007,000 after buying an additional 37,656 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services.

The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.